Ber-MAC3: new monoclonal antibody that defines human monocyte/macrophage differentiation antigen.
AUTOR(ES)
Backé, E
RESUMO
A new monoclonal antibody Ber-MAC3 is reported. It recognises a formol sensitive epitope of a not yet clustered monocyte/macrophage specific 140 kilodalton glycoprotein that is expressed on the cell surface and in the cytoplasm. In 30 cases of acute and chronic leukaemia, Ber-MAC3 staining was restricted to 15 myeloid leukaemias of M4 and M5 types. The tumour cells of two cases of true histiocytic malignancies were Ber-MAC3 positive, whereas those of all 280 malignancies of lymphocytic origin were negative. The latter included 52 cases of Hodgkin's disease and 41 cases of Ki-1 positive anaplastic large cell lymphomas which had previously been classified as true histiocytic lymphomas. Ber-MAC3 therefore seems to be of considerable value for selective identification of monocytes and macrophages at a certain stage of differentiation and seems to be suitable for diagnosing myelomonocytic or monocytic leukaemia and neoplasms of true histiocytic origin.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=496636Documentos Relacionados
- Ber-ACT8: new monoclonal antibody to the mucosa lymphocyte antigen.
- Human cytomegalovirus infection of the monocyte/macrophage lineage in bone marrow.
- Induced Expression and Association of the Mona/Gads Adapter and Gab3 Scaffolding Protein during Monocyte/Macrophage Differentiation
- Tumor necrosis factor-alpha modulates monocyte/macrophage apoprotein E gene expression.
- Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels